---
schema_version: "secwatch.filing_event.v1"
accession: "0000879169-23-000005"
form_type: "8-K"
ticker: "INCY"
cik: "0000879169"
company_name: "INCYTE CORP"
filed_at: "2023-02-07T23:59:59+00:00"
generated_at: "2026-06-19T23:30:06.703145+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Incyte reports FY2022 revenue $3.4B (+14%); Jakafi up 13%; provides 2023 guidance

## Summary
- FY2022 total revenues $3.39B (+14% YoY), net product rev $2.75B (+18%); GAAP diluted EPS $1.52, non-GAAP $2.78.
- Jakafi net rev Q4 $647M (+9%), FY $2.41B (+13%); 2023 guidance range $2.53–2.63B.
- Opzelura net rev Q4 $61M, FY $129M driven by atopic dermatitis and vitiligo launch; patent extended to 2040.
- GAAP net income $341M (vs $949M in 2021, which included a large tax benefit); cash & securities $3.2B.
- 2023 guidance: Jakafi $2.53–2.63B; R&D $1.61–1.65B GAAP; SG&A $1.05–1.15B GAAP.

## SEC filing metadata
- accession: 0000879169-23-000005
- form_type: 8-K
- ticker: INCY
- cik: 0000879169
- company_name: INCYTE CORP
- filed_at: 2023-02-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879169/000087916923000005/0000879169-23-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879169/000087916923000005/incy-20230207.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000879169-23-000005
- JSON: https://secwatch.observer/filing/0000879169-23-000005.json
- Plain text: https://secwatch.observer/filing/0000879169-23-000005.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.